Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17500
Corporate User License Price USD 750
Corporate User License Price INR 52500
Site License Price USD 500
Site License Price INR 35000
Request a Quote

Report Title

Pernix Therapeutics Holdings Inc (PTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Pernix Therapeutics Holdings Inc (PTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Pernix Therapeutics Holdings Inc (PTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Pernix Therapeutics Holdings Inc (PTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

Pernix Therapeutics Holdings Inc (Pernix Therapeutics) is a specialty pharmaceutical company that discovers, develops, and markets generic pharmaceutical products. The company's portfolio encompasses a fixed dose combination product prescribed to treat acute migraine; an extended-release (XR) opioid agonist that is indicated for pain severe management, and long-term opioid treatment; a non-narcotic, non-addictive, and non-scheduled prescription sleep aid to treat insomnia; an antibiotic for infections of middle ear; and indications for depressive disorder in adults. Its branded and generic pharmaceuticals products span the therapeutic areas of neurology, psychiatry, and pain management. The company serves drug wholesalers, retail drug stores, and mass merchandisers. It has subsidiaries in the US and Ireland. Pernix Therapeutics is headquartered in Morristown, New Jersey, the US.

Pernix Therapeutics Holdings Inc (PTX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Pernix Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Pernix Therapeutics Acquires Rights to Contrave/Mysimba from Orexigen Therapeutics for USD75 Million 13

Pernix Acquires Zohydro ER Business from Zogenix 14

Pernix Therapeutics Completes Acquisition of Treximet Tablets For Migraine From GlaxoSmithKline 16

Partnerships 18

Pernix Therapeutics Enters Into Co-Promotion Agreement With Osmotica Pharma For Khedezla ER Tablets 18

Cumberland Pharma Enters Into Co-Promotion Agreement With Pernix Therapeutics 19

Somaxon Pharma Enters Into Co-Marketing Agreement With CJ CheilJedang For Silenor 20

Particle Sciences Enters Into Co-Development Agreement With Pernix Therapeutics 21

Pernix Therapeutics Enters Into Co-Development Agreement For Pediatric Product 22

Licensing Agreements 23

Pernix Therapeutics Enters into Licensing Agreement with Recro Pharma 23

Pernix Therapeutics Enters Into Licensing Agreement For Prescription Product To Treat Gastroenterology Disease 24

Equity Offering 25

Pernix Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 25

Pernix Therapeutics Plans to Raise Funds through Public Offering of Shares 26

Pernix Therapeutics to Raise up to USD16 Million in Public Offering of Shares 27

Somaxon Pharma Completes Private Placement Of Shares For USD 3 Million 28

Pernix Therapeutics Completes Public Offering Of Shares For USD 21.3 Million 29

Debt Offering 31

Pernix Therapeutics Raises USD130 Million in Private Placement of 4.25% Notes Due 2021 31

Pernix Therapeutics Holdings Raises USD65 Million in Private Palcement of 8% Notes Due 2019 33

Pernix Therapeutics Holdings Raises USD220 Million in Private Placement of Notes 34

Pernix Therapeutics Completes Private Placement Of Notes Due 2019 For USD 65 Million 35

Asset Transactions 36

SI Pharma Acquires Cedax from Pernix Therapeutics 36

Breckenridge Pharma Completes Acquisition of Certain Generic Assets From Pernix Therapeutics For USD 30 Million 37

Acquisition 38

Pernix Therapeutics May Sell Itself 38

Woodfield Pharma Acquires Pernix Manufacturing From Pernix Therapeutics For USD 6.2 Million 39

Pernix Therapeutics Completes Acquisition Of Somaxon Pharma For USD 25 Million 40

Pernix Therapeutics Completes Acquisition Of Cypress Pharma And Hawthorn Pharma For USD 102 Million 42

Pernix Therapeutics Completes Acquisition Of Great Southern Laboratories For USD 6 Million 43

Pernix Therapeutics Holdings Inc-Key Competitors 44

Pernix Therapeutics Holdings Inc-Key Employees 45

Pernix Therapeutics Holdings Inc-Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Recent Developments 47

Financial Announcements 47

Aug 09, 2018: Pernix Therapeutics reports second quarter 2018 financial results 47

May 10, 2018: Pernix Therapeutics Reports First Quarter 2018 Financial Results 50

Mar 08, 2018: Pernix Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 51

Nov 07, 2017: Pernix Therapeutics Reports Third Quarter 2017 Financial Results 54

Jul 27, 2017: Pernix Therapeutics Reports Second Quarter 2017 Financial Results and Provides Business Update 57

Jul 20, 2017: Pernix Therapeutics Pre-Announces Certain Preliminary Second Quarter 2017 Financial Results 60

May 15, 2017: Pernix Therapeutics Reports First Quarter 2017 Financial Results and Provides Business Update 62

Mar 28, 2017: Pernix Therapeutics Announces Fourth Quarter And Full Year 2016 Financial Results 64

Corporate Communications 68

Feb 06, 2018: Pernix Announces Appointment of Lead Independent Director and Key Management Team Promotion 68

Nov 16, 2017: Pernix Therapeutics Announces Election of Two Healthcare Industry Veterans to Board of Directors 69

Oct 17, 2017: Pernix Therapeutics Announces Planned Departure of Chief Financial Officer 70

Appendix 71

Methodology 71

About GlobalData 71

Contact Us 71

Disclaimer 71

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Pernix Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pernix Therapeutics Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Pernix Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10

Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Pernix Therapeutics Acquires Rights to Contrave/Mysimba from Orexigen Therapeutics for USD75 Million 13

Pernix Acquires Zohydro ER Business from Zogenix 14

Pernix Therapeutics Completes Acquisition of Treximet Tablets For Migraine From GlaxoSmithKline 16

Pernix Therapeutics Enters Into Co-Promotion Agreement With Osmotica Pharma For Khedezla ER Tablets 18

Cumberland Pharma Enters Into Co-Promotion Agreement With Pernix Therapeutics 19

Somaxon Pharma Enters Into Co-Marketing Agreement With CJ CheilJedang For Silenor 20

Particle Sciences Enters Into Co-Development Agreement With Pernix Therapeutics 21

Pernix Therapeutics Enters Into Co-Development Agreement For Pediatric Product 22

Pernix Therapeutics Enters into Licensing Agreement with Recro Pharma 23

Pernix Therapeutics Enters Into Licensing Agreement For Prescription Product To Treat Gastroenterology Disease 24

Pernix Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 25

Pernix Therapeutics Plans to Raise Funds through Public Offering of Shares 26

Pernix Therapeutics to Raise up to USD16 Million in Public Offering of Shares 27

Somaxon Pharma Completes Private Placement Of Shares For USD 3 Million 28

Pernix Therapeutics Completes Public Offering Of Shares For USD 21.3 Million 29

Pernix Therapeutics Raises USD130 Million in Private Placement of 4.25% Notes Due 2021 31

Pernix Therapeutics Holdings Raises USD65 Million in Private Palcement of 8% Notes Due 2019 33

Pernix Therapeutics Holdings Raises USD220 Million in Private Placement of Notes 34

Pernix Therapeutics Completes Private Placement Of Notes Due 2019 For USD 65 Million 35

SI Pharma Acquires Cedax from Pernix Therapeutics 36

Breckenridge Pharma Completes Acquisition of Certain Generic Assets From Pernix Therapeutics For USD 30 Million 37

Pernix Therapeutics May Sell Itself 38

Woodfield Pharma Acquires Pernix Manufacturing From Pernix Therapeutics For USD 6.2 Million 39

Pernix Therapeutics Completes Acquisition Of Somaxon Pharma For USD 25 Million 40

Pernix Therapeutics Completes Acquisition Of Cypress Pharma And Hawthorn Pharma For USD 102 Million 42

Pernix Therapeutics Completes Acquisition Of Great Southern Laboratories For USD 6 Million 43

Pernix Therapeutics Holdings Inc, Key Competitors 44

Pernix Therapeutics Holdings Inc, Key Employees 45

Pernix Therapeutics Holdings Inc, Subsidiaries 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Pernix Therapeutics Holdings Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person